- OncoSec Medical (NASDAQ:ONCS) announces new positive interim data from its KEYNOTE-695 Phase 2b trial evaluating TAVO (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients.
- TAVO + KEYTRUDA led to a 30% ORR in the first 54 out of 100 planned patients (95%CI [18.0%, 43.6%]) (16/54), much higher than the primary efficacy endpoint of 20% ORR determined by blinded independent review.
- Complete response rate was 6% (3/54).
- 9% (5/54) patients had 100% reduction of target lesions.
- ORR was 35% (n=6/17) and 40% (n=6/15) in patients with Stage IV M1c/M1d disease and with prior exposure to ipilimumab, respectively.
- Median duration of response is currently 12.2 months (95% CI, 5.6-NE).
- Median study follow-up was 13.5 months.
- Only 5.4% Grade 3 treatment-related adverse events were observed.
- The data were will be presented at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting .
- OncoSec also announced pre-clinical data showing that CORVax12 triggers an immune response against the SARS-CoV-2 virus. CORVax12 combines OncoSec's TAVO with the National Institute of Health (NIH)'s COVID-19 "spike" protein.
- https://seekingalpha.com/news/3633684-oncosec-drops-11-despite-positive-data-from-tavo-mercks-keytruda-in-metastatic-melanoma
Monday, November 9, 2020
OncoSec drops despite positive data from TAVO + Merck's Keytruda in metastatic melanoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.